SCLERODERMA RENAL CRISIS: ARE THERE ANY HOPES FOR CHANGES?


Cite item

Full Text

Abstract

Clinical signs, pathogenesis, prognosis and treatment of scleroderma renal crisis are discussed

About the authors

- -

References

  1. Guerini S., Cavazzana I., Venturelli C. et al. Renal involvement in systemic sclerosis. G. Ital. Nefrol. 2007; 24(4): 295-310
  2. Teixeira L., Servettaz A., Mehrenberger M. Scleroderma renal crisis. Presse Med. 2006; 35 (12 Pt. 2): 1966-1974
  3. Horn H.C., Otte K.E., Jensen J.E. Renal crisis at the onset of systemic sclerosis. Ugeskr Laeger. 2003; 165(40): 3832
  4. Canet J.J., Castañé J., Alvarez M. et al. Scleroderma renal crisis sine scleroderma. Nephron. 2002; 90(1): 119-120
  5. Steen V.D. Renal involvement in systemic sclerosis. Clin. Dermatol. 1994; 12: 253 - 258
  6. Steen V.D. Scleroderma renal crisis. Rheum. Dis. Clin. North Am. 2003; 29(2): 315-333
  7. Reveille J.D., Owerbach D., Goldstein R. et al. Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma). J. Clin. Invest. 1992; 89: 1208 - 1213
  8. Steen V. Scleroderma renal crisis. Indian J. Med. Sci. 2007; 61(1): 71-72.
  9. Jimenez S.A., Derk C.T. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann. Intern. Med. 2004; 140: 37-50.
  10. Gϋndϋs O.H., Fertig N., Lucas M. et al. Systemic sclerosis with renal crisis and pulmonary hypertension: a report of eleven cases. Arthritis and Rheumatism. 2001; 44(7): 1663-1666
  11. Codullo V., Cavazzana I., Bonino C. et al. Serologic profile and mortality rates of scleroderma renal crisis in Italy. J. Rheumatol. 2009; 36(7): 1464-1469
  12. Brown A.N., Bolster M.B. Scleroderma renal crisis in pregnancy associated with massive proteinuria. Clin. Exp. Rheumatol. 2003; 21(1): 114-116
  13. Celikbilek M., Elsurer R., Afsar B. et al. Mixed connective tissue disease: a case with scleroderma renal crisis following abortion. Clin. Rheumatol. 2007; 26(9): 1545-1547
  14. Szigeti N., Fábián G., Czirják L. Fatal scleroderma renal crisis caused by gastrointestinal bleeding in a patient with scleroderma, Sjögren's syndrome and primary biliary cirrhosis overlap. J. Eur. Acad. Dermatol. Venereol. 2002; 16(3): 276-279
  15. Rhew E.Y., Barr W.G. Scleroderma renal crisis: new insights and developments. Curr. Rheumatol. Rep. 2004; 6(2): 129-136
  16. Steen V.D., Medsger T.A. Jr., Osial T.A. Jr. et al. Factors predicting development of renal involvement in progressive systemic sclerosis. Am. J. Med. 1984; 76(5): 779-786
  17. DeMarco P.J., Weisman M.H., Seibold J.R. et al. Predictors and outcomes of scleroderma renal crisis. The high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis and rheumatism. 2002; 46(11): 2983 - 2989
  18. Domsic R.T., Rodriguez-Reyna T., Lucas M. et al. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann. Rheum. Dis. 2010 Aug 2. [Epub ahead of print]
  19. Avouac J., Walker U., Tyndall A. et al. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J. Rheumatol. 2010; 37(7): 1488-1501
  20. Yamanishi Y., Yamana S., Ishioka S., Yamakido M. Development of ischemic colitis and scleroderma renal crisis following methylprednisolone pulse therapy for progressive systemic sclerosis. Intern. Med. 1996; 35(7): 583-586
  21. Steen V.D., Medsger T.A. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis and Rheumatism. 1998; 41(9): 1613 - 1619
  22. Lee S., Lee S., Sharma K. The pathogenesis of fibrosis and renal disease in scleroderma: recent insights from glomerulosclerosis. Curr. Rheumatol. Rep. 2004; 6(2): 141-148
  23. Аникина Н.В., Гусева Н.Г., Мач Э.С. Нарушения микроциркуляции в генезе склеродермической нефропатии. Тер. арх.1986; 8: 62 - 65
  24. Casoli P., Carretti C., Tumiati B. Scleroderma renal crisis as a possible complication of cyclosporin A withdrawal. Clin. Rheumatol. 1994; 13(1): 126-128
  25. Attoussi S., Faulkner M.L., Oso A., Umoru B. Cocaine-induced scleroderma and scleroderma renal crisis. South Med. J. 1998; 91(10): 961-963
  26. Grobner T., Prischl F.C. Gadolinium and nephrogenic systemic fibrosis. Kidney Int. 2007; 72(3): 260-264
  27. Lim Y.L., Lee H.Y., Low S.C. et al. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature. Clin. Exp. Dermatol. 2007; 32(4): 353-358
  28. Mouthon L., Mehrenberger M., Teixeira L. et al. Endothelin-1 expression in scleroderma renal crisis. Hum. Pathol. 2010 Oct 22. [Epub ahead of print]
  29. Canavese C., Mereu M.C., Aime S. et al. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness. J. Nephrol. 2008; 21(3): 324-336
  30. Grobner T., Prischl F.C. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure. Semin. Dial. 2008; 21(2): 135-139
  31. Lee S., Lee S., Sharma K. The pathogenesis of fibrosis and renal disease in scleroderma: recent insights from glomerulosclerosis. Curr. Rheumatol. Rep. 2004; 6(2): 141-148
  32. Ichikawa H., Amano T., Fukuda S. et al. A case of scleroderma renal crisis with massive pericardial effusion and positivity on antiphospholipid antibody test. Nippon Jinzo Gakkai Shi. 1998; 40(4): 295-300
  33. Katrib A., Sturgess A., Bertouch J.V. Systemic sclerosis and antineutrophil cytoplasmic autoantibody-associated renal failure. Rheumatol. Int. 1999; 19(1-2): 61-63
  34. Kamen D.L., Wigley F.M., Brown A.N. Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis in scleroderma - a different kind of renal crisis. J. Rheumatol. 2006; 33(9): 1886-1888
  35. Anders H.J., Wiebecke B., Haedecke C. MPO-ANCA-Positive crescentic glomerulonephritis: a distinct entity of scleroderma renal disease? Am. J. Kidney Dis. 1999; 33(4): e3
  36. Idée J.M., Port M., Medina C. et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology. 2008; 248(2-3): 77-88
  37. Bonnet F., Longy-Boursier M., Aparicio M. et al. Scleroderma renal crisis. 7 cases and review of the literature. Ann. Med. Interne (Paris). 1998; 149(5): 243-250
  38. Herndon T.M., Kim T.T., Goeckeritz B.E. et al. Alveolar hemorrhage and pulmonary hypertension in systemic sclerosis: a continuum of scleroderma renal crisis? J. Clin. Rheumatol. 2001; 7(2): 115-119
  39. Naniwa T., Banno S., Takahashi N. et al. Normotensive scleroderma renal crisis with diffuse alveolar damage after corticosteroid therapy. Mod. Rheumatol. 2005; 15(2):134-138
  40. Гусева Н.Г. Системная склеродермия и псевдосклеродермические синдромы. М., Медицина, 1993
  41. Gibney E.M., Parikh C.R., Jani A. et al. Kidney transplantation for systemic sclerosis improves survival and may modulate disease activity. Am. J. Transplant. 2004; 4(12): 2027-2031
  42. Гусев Н.Г., Аникина Н.В., Щербаков А.Б. Применение каптоприла при системной склеродермии. Тер. арх. 1992; 64(5): 100 - 102
  43. Steen V.D., Costantino J.P., Shapiro A.P., Medsger T.A. Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann. Intern. Med. 1990; 113(5): 352-357
  44. Gliddon A.E., Doré C.J., Black C.M. et. al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum. 2007; 56(11): 3837-3846
  45. DeMarco P.J., Weisman M.H., Seibold J.R. et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum. 2002; 46(11): 2983-2989
  46. Wigley F.M., Korn J.H., Csuka M.E. et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum. 1998; 41(4): 670-677
  47. Airò P., Rossi M., Scarsi M. et al. Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group. Clin. Exp. Rheumatol. 2007; 25(5): 722-727
  48. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002 Ann.Rheum.Dis. 2007; 66(7): 940-944
  49. Teixeira L., Mouthon L., Mahr A. et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann. Rheum. Dis. 2008; 67(1): 110-116
  50. Walker J.G., Ahern M.J., Smith M.D. et al. Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment. Intern. Med. J. 2003; 33(5-6): 216-220

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies